Our Development Pipeline
Timber is strategically building a development pipeline in rare dermatologic diseases that have no approved treatments. Our core development programs have all received Orphan Drug status. In addition, all of our investigational products have significant market expansion potential into additional rare and other broad dermatological conditions.
Expanded Access Statement
Timber Pharmaceutical’s current policy on expanded access is not to offer expanded access until such time that the company has thoroughly addressed the various logistical and regulatory components of such an offering. For more information, please contact email@example.com
TMB-001 (IPEG™ topical isotretinoin) is being developed for the treatment of moderate to severe subtypes of Congenital ichthyosis (CI).
TMB-003 (topical sitaxentan) is under preclinical evaluation for sclerotic skin diseases.